Revolution Medicines shared on LinkedIn:
“Our most defining moment wasn’t a breakthrough – it was a question.
Early in Revolution Medicines’ journey, a promising research program didn’t deliver the results we hoped for. Rather than defend our hypothesis, we asked why and followed the data where it led.
That experience helped shape how we approach science today: unexpected results aren’t necessarily dead ends. They can reveal something new, challenge how we think and point us in a different direction.
Explore the first chapter of Revolutionary by Nature, featuring Chief Scientific Officer Jan Smith’s perspective on following the science wherever it leads.”
Other articles about Revolution Medicines on OncoDaily.